The Ipsen Investment Case

Building a high-value sustainable pipeline Phase I Cabometyx + atezolizumab Solid tumors IPN59011 Phase II IPN60130 FOP Longer-acting neurotoxin mesdopetam PD-LID Ax IPN10200 Longer-acting neurotoxin Ax/Tx Phase III Cabometyx + atezolizumab 1L HCC Cabometyx + atezolizumab 2L NSCLC1 Cabometyx + atezolizumab 2L mCRPC2 Onivyde 2L SCLC1 Onivyde 1L PDAC² elafibranor² PBC Registration Cabometyx 2L RR DTC³ palovarotene FOP Dysport NDO IPSEN Innovation for patient care Oncology 1. Data Information shown as at the end of 2021. Rare Disease Neuroscience readout anticipated in H2 2022. 2. Data readout anticipated in 2023. 3. Regulatory decision (EU) anticipated in H1 2022. Ax: aesthetics; Tx: therapeutics; FOP: fibrodysplasia ossificans progressiva; PD-LID: Parkinson's disease - levodopa-induced dyskinesia; HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer; mCRPC: metastatic castration-resistant prostate cancer; SCLC: small-cell lung cancer; PDAC: pancreatic ductal adenocarcinoma; PBC: primary biliary cholangitis; RR DTC: radio- refractory differentiated thyroid cancer; NDO: neurogenic detrusor overactivity. 10

View entire presentation